Sulfatase variant for improved hydrolysis of sulfated dehydroepiandrosterone (DHEAS)
Sulfazyme™ is a collection of recombinant arylsulfatases engineered to hydrolyze steroid sulfates. There are three different arylsulfatases under this brand: Sulfazyme PaS (04E-270-005), Sulfazyme DS (04E-199-005) and Sulfazyme β–AS (04E-200-005). Compared to crude snail sulfatase, Sulfazyme PaS had fivefold higher recovery of terbutaline from human urine samples containing terbutaline sulfate as reported by Wang et al. (2018). Additionally, Lessard-Lord et al. (2021, 2023) used Sulfazyme PaS for room temperature hydrolysis of flavan-3-ol biomarkers and phenyl-γ-valerolactones in human urine samples; overall, sample incubation was reduced from six hours to five minutes relative to previous protocols. A new variant of Sulfazyme PaS, called Sulfazyme DS, has been genetically engineered for enhanced hydrolysis of dehydroepiandrosterone 3β-sulfate (DHEAS). Sulfazyme DS exhibits 7x and 38x higher activity towards cortisol 21-sulfate and DHEAS than Sulfazyme PaS, respectively.
